Viatris’ ophthalmic drug flunks Phase 3 study, company mulls next stepsnews2025-07-18T14:39:02+00:00July 18th, 2025|Endpoints News|
#IAS25: HIV activists, scientists press for change, fueled by excitement for new PrEP toolsnews2025-07-18T14:07:06+00:00July 18th, 2025|Endpoints News|
Sarepta patient dies in study for limb-girdle muscular dystrophy, raising more safety concernsnews2025-07-18T01:23:15+00:00July 18th, 2025|Endpoints News|
Bristol Myers, Pfizer launch DTC offering for Eliquis at 40% discountnews2025-07-17T15:57:45+00:00July 17th, 2025|Endpoints News|
UK government pledges “billions of pounds” for new research center in Essexnews2025-07-17T14:54:32+00:00July 17th, 2025|Endpoints News|
Massive proteomics study reveals new clues about Alzheimer’s and rekindles old onesnews2025-07-17T14:23:23+00:00July 17th, 2025|Endpoints News|
Novartis ups income guidance, initiates $10B share buybacknews2025-07-17T11:13:05+00:00July 17th, 2025|Endpoints News|
Sarepta lays off 500 people, adds black box warning to DMD therapynews2025-07-16T21:02:25+00:00July 16th, 2025|Endpoints News|
Endpoints livestream: Drugs and biomanufacturing in space with Varda CSO Adrian Radoceanews2025-07-16T13:47:58+00:00July 16th, 2025|Endpoints News|
#IAS25: Jeanne Marrazzo, NIAID director placed on leave, on ‘biggest threats’ to HIV medicinenews2025-07-16T13:41:18+00:00July 16th, 2025|Endpoints News|
